Demographic Characteristics of Participants in Trials Essential to US Food and Drug Administration Vaccine Approvals, 2010-2020.
作者信息
Zhang Audrey D, Puthumana Jeremy, Egilman Alexander C, Schwartz Jason L, Ross Joseph S
机构信息
Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
出版信息
J Gen Intern Med. 2022 Feb;37(3):700-702. doi: 10.1007/s11606-021-06670-3. Epub 2021 Mar 3.
Abstract
摘要
相似文献
1
Demographic Characteristics of Participants in Trials Essential to US Food and Drug Administration Vaccine Approvals, 2010-2020.2010 - 2020年美国食品药品监督管理局疫苗批准所需试验参与者的人口统计学特征
J Gen Intern Med. 2022 Feb;37(3):700-702. doi: 10.1007/s11606-021-06670-3. Epub 2021 Mar 3.
2
Speed, Evidence, and Safety Characteristics of Vaccine Approvals by the US Food and Drug Administration.美国食品和药物管理局批准疫苗的速度、证据和安全性特征。
JAMA Intern Med. 2021 Apr 1;181(4):559-560. doi: 10.1001/jamainternmed.2020.7472.
3
Comparison of COVID-19 Vaccine Approvals at the US Food and Drug Administration, European Medicines Agency, and Health Canada.比较美国食品药品监督管理局、欧洲药品管理局和加拿大卫生部批准的 COVID-19 疫苗。
JAMA Netw Open. 2021 Jun 1;4(6):e2114531. doi: 10.1001/jamanetworkopen.2021.14531.
4
Trends in US approvals: new biopharmaceuticals and vaccines.美国审批动态：新型生物制药与疫苗
Trends Biotechnol. 2006 Jul;24(7):293-8. doi: 10.1016/j.tibtech.2006.05.003. Epub 2006 Jun 6.
5
Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review.2005 - 2014年美国支持处方药补充适应症获批的疗效证据特征：系统评价
BMJ. 2015 Sep 23;351:h4679. doi: 10.1136/bmj.h4679.
6
Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration.美国食品药品监督管理局近期批准的仿制药特点。
JAMA Netw Open. 2019 Oct 2;2(10):e1913029. doi: 10.1001/jamanetworkopen.2019.13029.
7
Probability of Success and Timelines for the Development of Vaccines for Emerging and Reemerged Viral Infectious Diseases.新兴和再现病毒性传染病疫苗研发的成功率和时间表。
Ann Intern Med. 2021 Mar;174(3):326-334. doi: 10.7326/M20-5350. Epub 2020 Nov 24.
8
Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration.临床试验的局限性导致美国食品和药物管理局批准抗癌药物。
JAMA Intern Med. 2020 Aug 1;180(8):1108-1115. doi: 10.1001/jamainternmed.2020.2250.
9
U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.2016 年至 2018 年美国食品和药物管理局批准的肺癌、结直肠癌、乳腺癌和前列腺癌抗癌药物趋势。
Int J Technol Assess Health Care. 2020;36(1):20-28. doi: 10.1017/S0266462319000813. Epub 2019 Nov 28.
10
Characteristics of Postmarketing Studies for Vaccines Approved by the US Food and Drug Administration, 2006-2020.2006-2020 年美国食品药品监督管理局批准的疫苗上市后研究特征。
JAMA Netw Open. 2021 Apr 1;4(4):e218530. doi: 10.1001/jamanetworkopen.2021.8530.
引用本文的文献
1
Characterization of Individuals Interested in Participating in a Phase I SARS-CoV-2 Vaccine Trial.对有兴趣参与一项1期新型冠状病毒疫苗试验的个体的特征描述。
Vaccines (Basel). 2021 Oct 19;9(10):1208. doi: 10.3390/vaccines9101208.
本文引用的文献
1
Inclusion of Demographic-Specific Information in Studies Supporting US Food & Drug Administration Approval of High-Risk Medical Devices.支持美国食品和药物管理局批准高风险医疗器械的研究中纳入人口统计学特定信息。
JAMA Intern Med. 2017 Sep 1;177(9):1390-1391. doi: 10.1001/jamainternmed.2017.3148.
2
Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 U.S. Food and Drug Administration approvals.老年人、女性和少数族裔参与支持2011 - 2013年美国食品药品监督管理局批准的关键试验情况。
Trials. 2016 Apr 14;17:199. doi: 10.1186/s13063-016-1322-4.
Zotero 插件